Molsid
New generation of fluorogenic molcular probes for applications in Health & other industries
- Stage Product In Market
- Industry Biotechnology
- Location Lyon, France
- Currency EUR
- Founded August 2018
- Employees 10
- Incorporation Type Other
- Website molsid.com
Company Summary
AMR is a growing public health issue. WHO declares >10M deaths p/y due to AMR by 2050. Today, clinicians cannot clearly detect AMR in emergency. Available tests give results in 12-48hrs, leading to problems: patients are not isolated and spread bacteria and they receive wrong treatments. This raises AMR incidence and prolongs costly hospitalization. Our game-changing kit is easy to use and cost-efficient. In less than 2hrs it can save lives.
Team
-
Chairman20y of experience in innovation management, business set-up and strategy, team and project management, international marketing, MA Project Management
-
CEO25y of experience in finance, control and HR administration in various biotech and medtech companies, MSc Biology & MA Corporate finance
-
Jens HasserodtCo-founder and Scientific advisor25y of experience in organic chemistry, 10 patents filed, 16 publications, Professor and researcher at ENS Lyon, PhD chemistry
Advisors
-
Bernard Mandrand, PhD, Président Mandrand S.A.S., ex Dir Scientifique bioMérieux et LyonbiopôleUnconfirmed
Previous Investors
-
Bernard Mandrand, PhD, Président Mandrand S.A.S., ex Dir Scientifique bioMérieux et LyonbiopôleUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.